Earnings summaries and quarterly performance for BIOLIFE SOLUTIONS.
Executive leadership at BIOLIFE SOLUTIONS.
Roderick de Greef
Detailed
Chief Executive Officer
CEO
AM
Aby Mathew
Detailed
Chief Scientific Officer
KF
Karen Foster
Detailed
Chief Quality and Operations Officer
SA
Sarah Aebersold
Detailed
Chief Human Resources Officer
SW
Sean Werner
Detailed
Chief Technology Officer
TB
Todd Berard
Detailed
Chief Commercial Officer
TW
Troy Wichterman
Detailed
Chief Financial Officer
Board of directors at BIOLIFE SOLUTIONS.
Research analysts who have asked questions during BIOLIFE SOLUTIONS earnings calls.
MS
Matthew Stanton
Jefferies
4 questions for BLFS
Also covers: AZTA, CDXS, CYRX +5 more
AS
Anna Snopkowski
KeyBanc Capital Markets
3 questions for BLFS
Also covers: CYRX, RGEN, TKNO
CW
Chad Wiatrowski
TD Cowen
3 questions for BLFS
Also covers: CDXS, CTKB, MASS +4 more
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
3 questions for BLFS
Also covers: ACET, APYX, BHST +21 more
Thomas Flaten
Lake Street Capital Markets
3 questions for BLFS
Also covers: ACHV, AQST, ASRT +13 more
YC
Yi Chen
H.C. Wainwright & Co.
3 questions for BLFS
Also covers: ANGO, APDN, BLTE +22 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
1 question for BLFS
Also covers: ABCL, ABSI, ARWR +19 more
CB
Carl Byrnes
Northland Capital Markets
1 question for BLFS
Also covers: ALVO, BWAY, DRRX +6 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
1 question for BLFS
Also covers: ANGO, CDXC, CODX +8 more
Michael Okunewitch
Maxim Group
1 question for BLFS
Also covers: BLTE, BNGO, BRTX +11 more
Paul Knight
KeyBanc Capital Markets
1 question for BLFS
Also covers: A, AZTA, CDMO +13 more
ZA
Zach Adash
Stephens Inc.
1 question for BLFS
Recent press releases and 8-K filings for BLFS.
BioLife Solutions Announces Preliminary Q4 and Full Year 2025 Revenue
BLFS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- BioLife Solutions reported preliminary unaudited revenue from continuing operations of $24.8 million for the fourth quarter of 2025, representing a 20% increase from the prior year's fourth quarter.
- For the full year 2025, preliminary unaudited revenue from continuing operations reached $96.2 million, a 29% increase from 2024, and exceeded the high end of the previously raised guidance range.
- Following the divestiture of its evo product line in October 2025, BioLife Solutions is now positioned as a pure-play cell processing company.
- The company expects revenue growth and further expansion of adjusted EBITDA margin in 2026, with full 2026 financial guidance to be provided in February.
Jan 12, 2026, 1:03 PM
BioLife Solutions Issues Investor Presentation with FY 2025 Guidance
BLFS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- BioLife Solutions, Inc. released an investor presentation on November 17, 2025, providing an overview of its financial performance and market position.
- The company projects FY 2025 revenue guidance of $95-96 million, reflecting an anticipated 27-29% organic revenue growth.
- For the nine months ended Q3 2025, BioLife Solutions achieved a 25% Adjusted EBITDA Margin and a 65% Gross Margin.
- For Q3 2025, the company reported $25,958 thousand in total revenues and $6,968 thousand in Adjusted EBITDA.
- BioLife Solutions' products are integral to the cell-based therapy market, being specified in over 950 active global clinical trials and 16 commercially approved cell-based therapies.
Nov 17, 2025, 12:00 PM
BLFS Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Completes Strategic Divestiture
BLFS
Earnings
Guidance Update
M&A
- BioLife Solutions (BLFS) reported Q3 2025 revenue of $28.1 million, a 31% year-over-year increase, with cell processing revenue growing 33% to $25.4 million.
- Adjusted EBITDA for Q3 2025 reached $7.8 million, or 28% of revenue, up from 23% in the prior year, reflecting improved profitability.
- The company completed the sale of its Evo Cold Chain Logistics product line for approximately $25.5 million in cash in early October, which is expected to increase cash and marketable securities to approximately $125 million.
- Full-year 2025 cell processing revenue guidance was raised to $93-$94 million (26%-28% year-over-year growth), and total revenue guidance (adjusted for the Evo sale) was increased to $95-$96 million (27%-29% growth).
- This strategic divestiture allows BLFS to focus on becoming a pure-play cell processing company with an optimized product portfolio.
Nov 6, 2025, 9:30 PM
BioLife Solutions Reports Strong Q3 2025 Results and Raises Full-Year Guidance
BLFS
Earnings
Guidance Update
M&A
- BioLife Solutions reported Cell Processing revenue of $25.4 million for the third quarter of 2025, representing a 33% increase over Q3 2024. The company also achieved GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million, which was 28% of revenue.
- The company raised its 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million and its total revenue guidance to $95.0 million - $96.0 million, adjusted for the recent sale of its evo cold chain logistics subsidiary.
- BioLife Solutions completed the sale of its evo cold chain logistics business on October 6, 2025, for an aggregate sales price of $25.5 million in cash, positioning the company as a pure-play cell processing entity.
- As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $98.4 million.
Nov 6, 2025, 9:08 PM
BioLife Solutions Reports Strong Third Quarter 2025 Financial Results and Updates 2025 Guidance
BLFS
Earnings
Guidance Update
M&A
- BioLife Solutions reported total revenue of $28.1 million for Q3 2025, marking a 31% increase from Q3 2024, with Cell Processing revenue growing 33% to $25.4 million.
- For Q3 2025, the company achieved GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million, representing 28% of revenue.
- The company completed the sale of its evo cold chain logistics business on October 6, 2025, for $25.5 million in cash.
- BioLife Solutions raised its 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million and its full-year total revenue guidance to $95.0 - $96.0 million, adjusted for the evo sale.
- As of September 30, 2025, the company's biopreservation media is used in approximately 250 ongoing commercially sponsored clinical trials and embedded in 16 unique commercial cell and gene therapies.
Nov 6, 2025, 9:03 PM
BioLife Solutions announces subsidiary sale
BLFS
M&A
New Projects/Investments
- BioLife Solutions, Inc. (Nasdaq: BLFS) announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC, to Peli BioThermal.
- The transaction was for $25.5 million in cash, subject to certain adjustments.
- This divestiture is intended to streamline the company's product portfolio and operations, focusing resources on creating shareholder value through high-margin recurring revenue.
Oct 7, 2025, 12:04 PM
Quarterly earnings call transcripts for BIOLIFE SOLUTIONS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more